Definitive Healthcare Corp. (DH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: modest improvements in renewal rates, strong professional services revenue growth, and positive AI integration are offset by declining revenue, operating cash flows, and net dollar retention. The Q&A indicates cautious optimism with unresolved management responses. The strategic focus on AI and product innovation offers potential, but the lack of clear guidance and revenue decline tempers expectations. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Key Financial Performance
Total Revenue $61.5 million, down 1% year-over-year. Reasons for change: Outperformed revenue expectations on both subscription and professional services revenues.
Adjusted EBITDA $18.1 million, representing a margin of 29%, which was $1.1 million above the high end of guidance. Reasons for change: Strong profitability performance due to the underlying power of the business model and ongoing expense discipline.
Unlevered Free Cash Flow (Trailing 12 Months) Approximately $55 million. Reasons for change: Solid cash flow generation.
Subscription Revenues $58.5 million, declined 3% year-over-year or declined 7% excluding data partnership contributions. Reasons for change: Modest improvements in Q4 renewal rates year-over-year.
Professional Services Revenue Up 49% year-over-year. Reasons for change: Combination of delivering on traditional analytics engagements and ramp-up in digital activations activity.
Adjusted Gross Profit $50.2 million, flat from Q4 '24. Adjusted gross profit margin of 82%, expanded about 100 basis points year-over-year. Reasons for change: Short-term benefit to cost structure due to removal of one data source and onboarding of an additional source.
Adjusted Net Income $8.6 million, resulting in $0.06 of non-GAAP earnings per share. Reasons for change: Revenue beat and disciplined cost management.
Operating Cash Flows (Full Year 2025) $53.8 million, down 8% from the prior year. Reasons for change: Revenue decline partially offset by strong working capital performance.
Deferred Revenue $99 million, up 6% year-over-year. Reasons for change: Contributions from data partnership agreement.
Total Remaining Performance Obligations (RPO) Declined 18% year-over-year. Reasons for change: Greater percentage of new logo additions signed 1-year versus multiyear commitments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Fall Expansion Pack: Released in the second half of 2025, including a new claims data source, restoring claims data volumes to above historical levels.
Mobile Phone Data: Added to core reference and affiliation data for healthcare executives and providers.
Digital Activations: Signed nearly 30 agencies, with over one-third actively generating bookings. Outperformed growth targets for 2025.
AI Integration: Plans to integrate Gen AI into products starting with the flagship view platform in 2026.
HubSpot Integration: Introduced in Q4 2025, enhancing customer data integration capabilities.
Population Intelligence Platform: Adopted by a large nonprofit academic health system to improve patient segmentation and market share.
Partnership with Bombora: Launched a platform for curated ecosystem audiences, extending reach to platforms like The Trade Desk and Reddit.
Retention Rates: Improved year-over-year for three consecutive quarters, driven by coordinated customer-facing efforts.
Integration Automation: Reduced integration time by 25% in 2025, improving customer satisfaction.
Customer Success: Enhanced customer engagement processes, leading to better retention and satisfaction.
Data Differentiation: Focused on expanding and strengthening proprietary data assets.
Seamless Integrations: Deepened integrations with platforms like Snowflake and Databricks.
Innovation: Focused on digital engagement, partnerships, and AI-driven analytics.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Claims Data Market Disruption: The claims market underwent a significant data disruption over the past 12 to 18 months, impacting claims data volumes. Although volumes have been restored to above historical levels, the disruption has had lingering effects on operations and customer confidence.
Retention Challenges: Retention rates have shown improvement, but the company continues to face challenges in retaining customers, particularly due to past disruptions in claims data and organizational misalignments. This has impacted renewal rates and overall customer satisfaction.
Macroeconomic Environment: The challenging macroeconomic environment continues to exert pressure on the company's top-line performance and customer behavior, creating uncertainties in revenue growth and operational stability.
Lower Upsell Opportunities: Ongoing pressure in upsell opportunities has negatively impacted net dollar retention, limiting revenue growth potential. This is attributed to reduced customer spending and challenges in expanding existing accounts.
Shorter Contract Durations: A greater percentage of new customer contracts are being signed for shorter durations (one year instead of multiyear), which reduces long-term revenue visibility and stability.
Revenue Decline: Total revenue declined by 1% year-over-year in Q4 2025 and is projected to decline further by 6% to 9% in 2026, reflecting ongoing top-line pressures and challenges in customer retention and upselling.
Cost Structure Adjustments: Temporary reductions in cost of goods sold (COGS) due to changes in data sources have provided short-term financial relief, but these adjustments may not be sustainable in the long term.
Competitive Pressures: The company faces competitive pressures in maintaining its data differentiation and quality, which are critical to its value proposition. This includes challenges in integrating new data sources and maintaining proprietary advantages.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q1 2026: Expected total Q1 revenue of $54 million to $56 million, representing a revenue decrease of 5% to 9% year-over-year compared to Q1 2025.
Revenue Guidance for Full Year 2026: Expected revenue of $220 million to $226 million, reflecting a 6% to 9% decline year-over-year. Revenue is expected to remain roughly flat sequentially through the year with a modest uptick in the second half relative to the first half.
Adjusted EBITDA for Q1 2026: Expected adjusted EBITDA of $12 million to $13 million, representing a 22% to 23% adjusted EBITDA margin.
Adjusted EBITDA for Full Year 2026: Expected adjusted EBITDA of $53 million to $58 million, reflecting a full-year margin of 24% to 26%.
Adjusted Net Income for Full Year 2026: Expected adjusted net income of $21 million to $26 million, translating to earnings per share of $0.14 to $0.17 on 145.4 million weighted average shares outstanding.
Unlevered Free Cash Flow for 2026: Expected improvement in adjusted EBITDA to unlevered free cash flow conversion by several points in 2026 relative to 2025 due to lower planned CapEx spend.
Strategic Investments in 2026: Targeted investments in growth areas such as digital activation, partnership and distribution efforts, and Gen AI enablement of the View platform to drive upsell and cross-sell opportunities.
Retention and Revenue Growth: Focus on improving customer retention and returning the business to consistent revenue growth through strategic initiatives and operational improvements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the demand environment across your three end markets and any common themes from the large cohort of renewals in December and January?
A:The demand environment showed no significant change, but there were some positive signs like condensed sales cycles. Renewal rates improved modestly in Q4 year-over-year, and integrated customers renewed at higher rates. Over 60 integrated customers were added in Q4, contributing to confidence in the 2026 plan.
Q:Can you provide insights into the renewal profile across end markets, particularly life sciences and pharma?
A:Gross dollar retention improved by 2 points year-over-year, driven by enterprise customers in life sciences. However, net dollar retention declined due to fewer upsell and cross-sell opportunities. The company has remediated claims data disruption and added new data sources, positioning itself for stronger performance in 2026.
Q:How does the growth outlook for 2026 reconcile with customer count declines and ARPU trends?
A:The company expects modest improvement in renewal rates and growth in diversified and provider segments, which are smaller than life sciences accounts. The business mix shift, rather than churn, is driving changes in ARPU trends.
Q:How is AI impacting customer conversations and the company's offerings?
A:AI is seen as a competitive advantage, enhancing health care-specific workflows and use cases. The company’s differentiated data supports AI applications, and the integration of generative AI will democratize platform use, unlocking more value for customers.
Q:When is net dollar retention (NDR) expected to improve?
A:NDR is expected to improve within 2026, with 2025 marking the bottom. Investments in product innovation, additional data, and claims data remediation are expected to drive this improvement.
Q:Are there any refinements in the go-to-market strategy to drive better upsells?
A:The company has integrated its go-to-market and customer success teams, leading to higher win rates and shorter sales cycles. Investments in AI and product innovation are expected to enhance upsell and cross-sell opportunities.
Q:How quickly are product updates communicated to the market, and how do they impact renewals?
A:Product updates like the fall expansion pack were introduced at the start of Q4, but their impact on renewals is expected to be more visible in Q1 and Q2 of 2026. The company anticipates these updates to boost renewals and open upsell opportunities.
Q:What is the status of claims data remediation and its impact on revenue?
A:Claims data issues have been resolved, with volumes and quality restored to historical levels or better. This remediation is expected to reduce downsell pressure and support revenue recovery.
Q:What are the dynamics in the life sciences end market regarding renewals and sales activity?
A:Life sciences showed stabilization with gross dollar retention improving by 200 basis points. Downsells due to claims data disruption have been a challenge, but long-standing relationships and high logo retention rates provide a stable foundation for recovery.
Q:What are the focus areas and timing for organic innovation spend?
A:The company is focusing on AI-enabled product roadmaps, with beta programs launching in Q1 and general availability expected in Q2 of 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the magnitude of net dollar retention (NDR) recovery in 2026, stating only a modest improvement is expected. Additionally, they did not quantify the revenue impact of claims data remediation or provide detailed timelines for product innovation returns.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI core
AI model
AI way
AI workflow
APIs lake
CEO objective
CRM connector
DH advantage
DSP Reddit
Databricks introduction
Definitive AI
Definitive Healthcare
Desk
agency
analytics
asset element
audience
care provider
claim market
customer engagement
customer satisfaction
differentiation
distribution
domain expertise
ease
ecosystem
foundation
goal customer
improvement customer
market disruption
outpatient
priority pillar
promise
service line
system insight
use case
year
DH Transcript
Definitive Healthcare Corp. (DH) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents mixed signals: modest improvements in renewal rates, strong professional services revenue growth, and positive AI integration are offset by declining revenue, operating cash flows, and net dollar retention. The Q&A indicates cautious optimism with unresolved management responses. The strategic focus on AI and product innovation offers potential, but the lack of clear guidance and revenue decline tempers expectations. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Definitive Healthcare Corp. (DH) Q3 2025 Earnings Call Transcript
Unknown11-6
Despite some positive indicators like increased operating cash flows and improved renewal rates, the overall sentiment is negative due to declining revenue guidance, subscription revenue decline, and management's vague responses on critical renewal issues. The Q&A highlighted budget constraints, particularly in life sciences, and expected gross margin pressure. These factors suggest a challenging environment, likely leading to a negative stock price reaction.
Definitive Healthcare Corp. (DH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
Definitive Healthcare Corp. (DH) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture: strong Q2 renewals and operational improvements are positives, but cautious guidance and challenges in life sciences weigh negatively. The company's focus on customer success and integration capabilities is promising, yet macroeconomic uncertainties and a decline in subscription revenues temper optimism. The Q&A section reveals cautious sentiment from analysts, especially regarding renewal timing and upsell pressures. Without significant catalysts like new partnerships or guidance changes, the stock is likely to remain stable in the near term.
DH Slides
Definitive Healthcare Q4 2025 slides: profit gains amid revenue decline2026-02-26
Definitive Healthcare Q3 2025 slides: Revenue decline continues despite earnings beat2025-11-06
Definitive Healthcare Q2 2025 slides: revenue decline continues but exceeds guidance2025-08-07
Definitive Healthcare Q1 2025 slides: revenue declines 7% YoY, beats guidance2025-05-08
DH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
